Asian Journal of Research in Pharmaceutical Sciences

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Mechanistic Approach to Determination of Anti-diabetic Activity of Calystegia Sepium R.Br. Flowering Plants in Normal and Streptozotocin Induced Rats


Affiliations
1 Institute of Pharmaceutical Science and Research centre, Bhagwant University, Ajmer, India
     

   Subscribe/Renew Journal


The Hypoglycemic effect of water and ethanol extracts of Calystegia sepium flowering plants has been evaluated and compared its Hypoglycemic effect of flowering plants with Glibenclamide in Euglycemic and Hyperglycemic Wistar rats. Male Wistar rats were orally administered Alcoholic and Water extracts of Calystegia sepium flowering plant and investigated for Hypoglycemic activity in Normal and Streptozotocin (STZ)-induced diabetic rats and compared their effect with Glibenclamide [Single dose one day study and multiple dose15 day study] Blood glucose levels were estimated at 0th, 5th, 10th and 15th day by Kit method and on 15th day lipid profiles were also estimated and other parameters like insulin estimation, insulin tolerance test, and glucose uptake by isolated hemi-diaphragm was estimated. The alcoholic and water extract of Calystegia sepium flower in plant exhibited significant Hypoglycemic and Hypolipidemic effect in Euglycemic and Hyperglycemic rats. The study reveals the hypoglycemic and hypolipidemic activity of alcoholic and water extract of Calystegia sepium flowering plants in euglycemic and Streptozotocin induced diabetic rats. The extract seems promising for the development of a phyto-medicine for a Diabetes mellitus.

Keywords

Diabetes Mellitus, Antihyperglycemic, Hypolipidemic, Euglycemic Calystegia Sepium.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Lernmark A, Ott L. Nature Genet. 1998.19: 213-14.

  • National Institute of Diabetes, Digestive and Kidney Disease, National Institute of Health. National Diabetes Information Clearinghouse 1 Information Way Bethesda, MD 20892-60.

  • Ratner RE, Basciano H, Federico L, Adeli K. Controlling post prandial hyperglycemia. Fructose, insulin resistance, and metabolic dyslipidemia. Nutrition and Metabolism2 .American J of Cardiology, 1005;88:1-5.

  • Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes. Diabetes Care 26:1277-94.

  • Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 1004;27:1047-53.

  • Ashok K, Tiwari J, Madhusudana Rao. Diabetes mellitus and multiple therapeutic approaches of phytochemicals. Present status and future prospects Pharmacology Division and Natural Product Laboratory, Organic-I Division, Indian Institute of Chemical Technology, Hyderabad: India.

  • Roa K, Kirishna M, et al. Trop J Pharm Res June 2004;3(1) 305- 09.

  • Srivastava A, Shukla YN. Aryl esters and a Coumarin from Calystegia sepium. Ind J of Chem 1998; 37(B):192-4.

  • Shukla YN, Anil Srivastava, Sunil Kumar, Sushil Kumar. Coumarin glycoside from Argyreia speciosa flowerin plant. Indian Drugs 2001;38:487-8.

  • Shukla YN, Anil Srivastava Sunil Kumar, SushilKumar. Phytotoxic and antimicrobial constituents of Argyreia speciosa and Oenothera biennis, J Ethnopharmacol 1999;67:241-5.

  • Ghokhle AB, Damre AS, Kulkarni KR, Saraf MN. Preliminary evaluation of anti-inflammatory and antiarthritic activity of S. lappa, Argyreia speciosa and Argyreia asper. Phytomedicine 2002;9:433-7.

  • Kartik R, Ojha SK, Rao CV, Malhotra S, Pushpgadanp. Ethnopharmacological Evaluation Argyreia speciosa (roxb) sweet for wound healing and anti-Inflammatory activity. National seminar on new millennium strategies for quality safety and GMP’s of herbal drug product NBRI, Lucknow: 2003; 42.

  • Shukla YN, Anil Srivastava, Sunil Kumar, SushilKumar. Phytotoxic and antimicrobial constituents of Argyreia speciosa and Oenothera biennis, J Ethnopharmacol 1999;67:241-5.

  • Ghokhle AB, Damre AS, Saraf MN. Investigation into immunomodulatory Activity of Argyreia speciosa. J Ethnopharmaco 2003;84:109-14.

  • Habbu PV, Hanumanthachar J, Kulkarni VH, Das SK, Navneet K. Memory Improving Effect of Arygeria speciosa in Mice. Natural Products an Ind J 2007;3(1); 1-5.

  • Habbu PV, Shastry RA, Mahadevan KM, Hanumanthachar J, Das SK. Hepatoprotective and antioxidant effects of Arygeria speciosa in rats. Afr J Traditional, Complementary and alternative medicines (in press).

  • Iyer S.R. Type 2 Diabetes Express Highway, Where is the 'U'Turn. Japi, 2003;51: 495-500.

  • The Expert Committee on the Diagnosis and Classification of Diabetes mellitus: Report of the Expert Committee on the Diagnosis and Classification Of Diabetes mellitus. Diabetes Care, 2004;27: 5-10.

  • Harris RA. Metabolic Interrelationships. Publication, (13) 1997; 525.

  • Sartiel AR. New perspectives into the molecular pathogenesis and treatment of Type-2 Diabetes. Cell, 2001;104:517-29.

  • Mann GE, Yudilevich DL, Sourevia L.Regulation of Amino acid and Glucose transporters in endothelial and smooth muscle cell. Physiol Rev, 2003;83: 183-252.

  • Carlson JC, Koterski S, Sciotti RJ, Poccard JB, Rondinone CM.Enhanced basal activation of mitogen activated protein kinases in adipocytes from Type- 2 Diabetes potential role of p38 in down regulation of GLUT-4expression. Diabetes, 2003;53:634-41.

  • Shepherd PR, Kahn BB. Glucose transporters and insulin action, implication for insulin resistance and Diabetes mellitus. N Eng J Med 1999;341(4):248-55.

  • Mathis DL, Lence, Benoist C. β-cell death during progression to diabetes Nature, 2001;414(13):792-98.

  • Taylor SI, Scriver CR, et al. The Metabolic and Molecular Basis of Inherited Disease, New York: McGraw-Hill, 1995; 843-83.

  • Powers AC. Diabetes mellitus, Harrison's Principles of Internal Medicines, Eugene Braunwald New York: McGraw-Hill Medical Publishing Division, 2001. 2108-37.

  • Saltiel RA, Kahn CR. Insulin signaling and the regulation of glucose and lipid metabolism. Nature, 01; 414(13):799-06.

  • Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in β-cell function. Nature, 2001; 414(13):788-91.

  • Guyton AC. The Liver as an Organ.Textbook of Medical Physiology, W.B. Saunders Co. Prism Books Pvt. Ltd. Bangalore India: 1991. 771-74.

  • Ganong WF. Energy Balance, Metabolism and Nutrition in Review of Medical Physiology, Stamford: Appleton-Lange 1999. 267-02.

  • Peter J. Watkins. ABC of Diabetes retinopathy. British Medical J 2003; 326: 924-26.

  • Anthony OC. Neurologic Disorders of Diabetes mellitus. Diabetes, 1965; 14(7): 424-29.

  • Krall LP, Rachmiel L, Donald B, Gordon C, Ronald CW. The History of Diabetes Mellitus, New Delhi: B.I. Waverly Pvt. Ltd.1996: 1027.

  • Hellman B, Gylfe E, Grapengiesser E, Dansk H, Salehi A. Insulin oscillations--clinically important rhythm. Antidiabetics should increase the pulsative component of the insulin release Swedish. Lakartidningen: 2007 104 (32-33): 2236-9.

  • William CW, Robert G, Bennett, Frederick GH. Insulin Degradation: Progress and Potential. Endocrine Reviews. 1998:19 (5): 608-24.

  • Diabetes Atlas: International Diabetes Federation, Brussels. 2nd ed .2004.

  • Position Statement. International Diabetes Federation, Brussels: 2005.

  • Richter B, Neises G. Human insulin versus animal insulin in people with diabetes mellitus. Cochrane Database of Systematic Reviews 2005.vol 1.

  • Dawn E, De Witt, Irl BH. Outpatient Insulin Therapy in Type-1 and Type-2 Diabetes mellitus. Jama: 2003;289(17): 2254-64.

  • Peden N, Ray W, Newton JF. Oral hypoglycemic agents. British Medical J 1983;280: 1564-67.

  • Kirpichnikov D, Samy I, McFarlane, James R S. Metformin an Update. Ann Inten Med 2002;137(1): 25-33.

  • Bailey CJ, Potential new treatments for type-2 Diabetes. 2000;21: 259-65.

  • Mudaliar S, Robert RH. New Oral therapies for Type 2 Diabetes mellitus The Glitazones or Insulin Sensitizer. Annu Rev Med 2001;52: 239-57.

  • Miles J M, Insulin in the Early Management of Diabetic Complications, Japi: 2003;51: 501-05.

  • Buse JB, Christian W, David GM. Amylin Replacement with Pramlintide in Type-1 and Type-2 Diabetes, A Physiological Approach to Overcome Barriers with Insulin Therapy ,Clinical Diabetes. 2002;20: 137-44.

  • David BR, Kirk WJ, Erik JH, John MN, Dane G, Tyson RK, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. 2003;52: 588-95.

  • Claude K, Denis R, Jean G, Jean PP. Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes. 2002;51: 2363-6.

  • Gary WC, Kirk J, Werner R, Pascale P, Effie T, Linda X, et al. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats. 2002;51: 2903-06.

  • Raija M, Christopher JP, Muriel C, Dorothy B, Philip S, Hannete Y, et al. Effects of insulin and Acipimox on VLDL1 and VLDL2 Apolipoprotein B production in normal subjects. 1998; 47: 779- 87.

  • Moller DE. New drug targets for type-2 Diabetes and the metabolic syndrome. Nature, 2001;414(13): 821-27.

  • Saltiel A R. New Perspectives into the Molecular Pathogenesis and Treatment of Type-2 Diabetes Cell, 2001;104: 517-29.

  • Chattopadhyay S, et al. Animal models in experimental diabetes mellitus, Ind J Exp Bio 1997;35(11): 1141-45.

  • Szkudelski T. The Mechanism of Alloxan and Streptozotocin Action in B-cells of the Rat Pancreas. Physiol Res 2001;50: 536- 46.

  • Rerup CC. Drugs producing diabetes through damage of the insulin secreting cells. Pharmacological Reviews, 1970;22(4): 485-18.

  • Vogel HG, Wolfgang HV. Drug Discovery and Evaluation - Pharmacological Assays, Germany: Springer, 1997: 757.

  • Gregor, Wesley H, Martin JM, Williamson JR, Lacy PE, Kipnis DM. A study of the Diabetic syndrome Produced in Rats by Anti- Insulin Serum, 1963;12: 73-81.

  • Karasik A, Hattori M, Kahn RC, Weir GC. Use of Animal Models in the Study of Diabetes, in Joslin's Diabetes mellitus, New Delhi: BI Waverly Pvt. Ltd.1996, 318-41.

  • Vavra JJ, Deboer C, Dietz A, Hanka LJ, Sokolski WT. Streptozotocin a new antibacterial antibiotic. Antibiot Annu 7: 1959; 230-5.

  • Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by Streptozotocin or by alloxan. Lancet 1 (7544) 1968; 670-1

  • Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW. Treatment of multiplehormone- producing malignant islet-cell tumour with Streptozotocin. Lancet 2 (7574) 1968: 895-8.

  • Wang Z, Gleichmann H .GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of Streptozotocin in mice. 1998; 47 (1): 50-6.

  • Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity Specific enhancement in GLUT2-expressing cells. 1994;43 (11): 1326-33.

  • Lown JN, Mc Laughlin LW, Chang Y. Mechanisms of action of 2-halo ethyl nitrosoureas on DNA and its relations to their antileukemic properties. Bioorg Chem 1979;7:97-110.

  • Doux SP, Woodley SE, Palton NJ, Wilson GL. Mechanism of nitrosourea induced? Cell damage: Alteration in DNA. 1986;35: 866-72.

  • Portha B, Blondel O, Serradas P, Mc Evoy R, Girox MH, Kergoat, et al. The rat models of non-insulin dependent diabetes induced by neonatal Streptozotocin. Diabete Metab 1989;15:61- 75.

  • Okamato H. Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin dependant diabetes. Mol Cell Biochem 1981;37:43-61.

  • Okamato H, Takaswa S. Recent advances in the Okamato model the cyclic ADP-Ribose signal system and the regulating gene protein Reg receptor system in? Cells. 2002;51(3):462-73.

  • Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillarire BD, et al. Experimental NIDDM: Development of a new model in adult rats administered Streptozotocin and nicotinamide. 1998;47:224-9.

  • Larsen MO, Rolin B, Wilken M, Carr RD, Gotfredsen DF. Measurements of insulin secretory capacity and glucose intolerance to predict pancreatic? Cell mass in vivo in the nicotnamide/streptozotocin Göttingen mini pig, a model of moderate insulin deficiency and diabetes. 2003;52:118-23.

  • Fierabracci V, De Tata V, Pocai A, Novelli M, Barbera A, Masiello P. Oral tungstate treatment imporves only transiently alteration of glucose metabolism in new rat model of type 2 diabetes. Endocrine 2002;19:177-84.

  • Rebel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, et al. NN221: A long-acting glucagons-like peptide-1 derivative with antidiabetic in glucose tolerant pigs. Eur J Pharmacol 2002;451:217-25.

  • Novelli M, Fabregat ME, Fernandez-Alvarez J, Gomis R, Masiello P. Metabolic and functional studies on isolated islets in a new rat model of type 2 diabetes. Mol Cell Endocrinol 2001;175:57-66.

  • Portha B, Levancher C, Picolon L, Rosselin G. Diabetogenic effect of Streptozotocin in the rat during the prenatal period. 1974;23:883-95.

  • Portha B, Picolon L, Rosselin G. Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 1979;17:371-7.

  • Junod A, Lambert AE, Stanffacher W, Reynold AE. Diabetogenic action of Streptozotocin: relationship of the dose to metabolic response. J Clin Invest 1969;48:2129-39.

  • Oliver B, Daniel B, Portha B. Relation of insulin deficiency to impaired insulin action in NIDDM adult rat given Streptozotocin as neonates. 1989; 38:610-17.

  • Bonnier-Weir S, Trent DE, Honey RN, Weir GC. Response to neonatal islets to Streptozotocin: Limited? Cell regeneration and hyperglycemia. 1981; 30:64-9.

  • Weir GC, Clore EE, Zma-Chinsky CJ, Bonnier-Weir S. Islet secretion in new experimental model for non-insulin dependant diabetes. Diabetes Metabolism Rev 1981;30:590-5.

  • Daniel Porte JR. cells in type 2 diabetes mellites. Diabetes 1991;40:116-80.

  • Matthews DR. Physiological implications of pulsatile hormone secretion. Ann NY Acad Sci 1991;618:28-37.

  • Charles JG, Donnia JK, David SW, David MM. Decrease insulin and glucagons pulse amplitude accompanying? Cell deficiency induced by Streptozotocin in Baboons. Diabetes 1989;38:925-31.

  • Lang DA, Matthews DR, Burnett M, Turner RE. Brief irregular oscillation of basal plasma insulin and glucose concentration in diabetic man. Diabetes 1981;30:43-9.

  • Polonsky KS, Given BD, Hirsch I, Tillil H, Sharpiro ET, Beebe C, et al. Abnormal patterns of insulin secretion in non-insulin dependant diabetes mellitus. N Eng J Med 1988;318:1231-9.

  • Girox MH, Portha B, Kergoat M, Bailbe D, Picon L. Glucose insensitivity and amino acid hypersensitivity of insulin release in rat with non-insulin dependant diabetes. A study with perfused pancreas. 1983;32:445-51.

  • Li Y, Wen S, Kota BP, Peng G, Qian Li G, Yamahara J et al. Punica granatum flower extract, a potent - glucosidase inhibitor, improves postprandial hyperglycemia in Zucker diabetic fatty rats. J Ethinopharmacol 2004;99:239-44

  • Siddique O, Sun Y, Lin JC , Chein YW. Facilitated transdermal transport of insulin. J. Pharmacol. Sci.1987; 76, 341-45.

  • Friedewald WT, Levy RI, Fredrickson DS. Estimation of lowdensity lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin. Chem.1972 ;18: 499.

  • Chattopadhyay RR, Sarkar SK, Ganguly S, Banerjee RN, Basu TK. Effect of extract of leaves of Vinca rosea Linn., on glucose utilization and glycogen deposition by isolated rat hemidiaphragm. Ind. J. Physiol. Pharmacol. 1992; 36(2): 137-38.

  • Ghosh R, Sharatchandra KH, Rita S, Thokchom IS. Hypoglycemic activity of Ficus hispida (bark) in normal and diabetic rats. Ind. J. Pharmacol. 2004; 36 (4), 222-25.

  • Swanston-Flatt SK, Flatt PR, Day C, Bailey CJ. Traditional dietary adjuncts for the treatment of diabetes mellitus. Proc. Nut. Soc. 1991; 50: 641-51.

  • Gray AM, Flatt PR. Nature’s own pharmacy: the diabetes perspective. Proc. Nut. Soc. 1997; 56: 507-17.

  • Gray AM, Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant Viscum album (mistletoe). J. Endocrinol. 1999; 160: 409-14.

  • World Health Organization. Second Report of the WHO Expert Committee on Diabetes Mellitus. Technical Report Series. 646. 1980; pp.66, Geneva: World Health Organization.

  • Kasiviswanath R, Ramesh A, Kumar KE. Hypoglycemic and antihyperglycemic effect of Gmelina asiatica Linn. in normal and Alloxan-induced diabetic rats. Biol. Pharm. Bull.2005;28:729-32.

  • Sieher FE, Traystman RJ. Ethical Issues Involved in the Development of Animal Models for Type I Diabetes. ILAR Journal. 1993; 35: 1.

  • Wessler S. Animal Models of Thrombosis and Hemorrhagic Diseases. Proceedings of the Workshop on Animal Models of Thrombosis and Hemorrhagic Diseases, the Institute of Laboratory Animal Resources, U.S. Department of Health, Education, and Welfare. , Washington, D.C, 1976; pp. xi-xvi.

  • Matti R, Das UK, Ghosh D. Attenuation of hyperglycemia and hyperlipidemia in streptozotocin-induced diabetic rats by aqueous extract of seed of Tamarindus indica. Biol. Pharm. Bull. 2005; 28(7): 1172-76.

  • Sharma SB, Nasir A, Prabhu KM, Murthy PS, Dev G. Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of Eugenia jambolana in alloxan-induced diabetic rabbits J. Ethanopharmacol. 2003; 85: 201-6.

  • Ananthan R, Latha M, Pari L, Baskar C, Narmatha V. (2004) Modulatory effects of Gymnema montanum leaf extract on alloxan induced oxidative stress in wistar rats. Nutrition,2004 ;20: 280-85. 50. Goldberg RB. Lipid disorders in diabetes. Diabetes Care. 1981; 4: 561-72.

  • Pathak RM, Ansari S ,Mahnood A. Changes in chemical composition of intestinal brush border membrane in alloxan induced chronic diabetes. Ind. J. Exp. Biol.1981; 9: 503-05.

  • Rajkumar M, Uttam KD, Debidas G. Attenuation of hyperglycemia and hyperlipidemia in streptozotocin-induced diabetic rats by aqueous extract of seed of Tamarindus indica. Biol. Pharm. Bull.2005; 28: (7): 1172-76.

  • Punitha R, Manoharan S. Antihyperglycemic and antilipidperoxidative effects of Pongamia pinnata (Linn.) Pierre flowers in alloxan induced diabetic rats. J. Ethanopharmacology. 2006;105: 39-46.

  • Shani J, Goldschmied A, Joseph B, Ahronoson Z, Sulman FG. Hypoglycemic effect of Trigonella foenum graecum and Lupinus terminis (Leguminosae) seed and their major alkaloids in alloxan diabetic and normal rats. Archives Internationals De Pharmacodynamic Et De Therapie. 1974; 210: 27-31.


Abstract Views: 351

PDF Views: 4




  • Mechanistic Approach to Determination of Anti-diabetic Activity of Calystegia Sepium R.Br. Flowering Plants in Normal and Streptozotocin Induced Rats

Abstract Views: 351  |  PDF Views: 4

Authors

Kumari Anjali Jain
Institute of Pharmaceutical Science and Research centre, Bhagwant University, Ajmer, India

Abstract


The Hypoglycemic effect of water and ethanol extracts of Calystegia sepium flowering plants has been evaluated and compared its Hypoglycemic effect of flowering plants with Glibenclamide in Euglycemic and Hyperglycemic Wistar rats. Male Wistar rats were orally administered Alcoholic and Water extracts of Calystegia sepium flowering plant and investigated for Hypoglycemic activity in Normal and Streptozotocin (STZ)-induced diabetic rats and compared their effect with Glibenclamide [Single dose one day study and multiple dose15 day study] Blood glucose levels were estimated at 0th, 5th, 10th and 15th day by Kit method and on 15th day lipid profiles were also estimated and other parameters like insulin estimation, insulin tolerance test, and glucose uptake by isolated hemi-diaphragm was estimated. The alcoholic and water extract of Calystegia sepium flower in plant exhibited significant Hypoglycemic and Hypolipidemic effect in Euglycemic and Hyperglycemic rats. The study reveals the hypoglycemic and hypolipidemic activity of alcoholic and water extract of Calystegia sepium flowering plants in euglycemic and Streptozotocin induced diabetic rats. The extract seems promising for the development of a phyto-medicine for a Diabetes mellitus.

Keywords


Diabetes Mellitus, Antihyperglycemic, Hypolipidemic, Euglycemic Calystegia Sepium.

References